About CLOVER BIO-B Company

We are a commercialized global biopharmaceutical company dedicated to saving lives and improving global health with innovative vaccines. Our mission is to use transformative science and global partnerships to bring innovative vaccines to the world and benefit more people. Relying on the comprehensive R&D capabilities of the Trimer-Tag technology platform, internal production and commercial capabilities to develop innovative vaccines, and strong partnerships at home and abroad, Clover Biotech has established a diverse pipeline of vaccine candidates, hoping that our vaccine can prevent more diseases and help reduce the burden on public health. Today, with comprehensive R&D capabilities, production and commercialization capabilities, and strong partnerships with relevant organizations distributed around the world, we have two authorized vaccines, the COVID-19 booster vaccine and the quadrivalent seasonal influenza vaccine. We are also promoting self-developed candidate vaccines for pre-fusion F antibody respiratory syncytial virus (RSV) in clinical trials based on proven Trimer-Tag platforms and proprietary stable mutation technology. The potential best-in-class protective efficacy of our RSV vaccine candidate is strongly guaranteed, and at the same time has potential best-in-class comprehensive efficacy and safety. Its differentiated advantages are expected to meet the unmet medical needs of the current global RSV vaccine market (joint vaccination and revaccination).